57,474 Shares in DexCom, Inc. $DXCM Bought by Fideuram Asset Management Ireland dac

Key Points

• Fideuram Asset Management Ireland dac opened a new position in DexCom, buying 57,474 shares valued at about $3.8 million in the fourth quarter.
• DexCom shares were up 3.0% and opened at $72.34, with the stock trading between a 52-week low of $54.11 and high of $89.98.
• The company recently posted better-than-expected quarterly results, earning $0.56 per share versus $0.47 expected, on revenue of $1.19 billion, up 15% year over year.

Fideuram Asset Management Ireland dac acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 57,474 shares of the medical device company's stock, valued at approximately $3,815,000.

Other large investors have also modified their holdings of the company. CVA Family Office LLC boosted its holdings in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company's stock worth $30,000 after buying an additional 147 shares during the period. ORG Partners LLC boosted its holdings in shares of DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company's stock worth $34,000 after buying an additional 281 shares during the period. Spire Wealth Management boosted its holdings in shares of DexCom by 113.8% during the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company's stock worth $38,000 after buying an additional 305 shares during the period. Aventura Private Wealth LLC bought a new stake in shares of DexCom during the 4th quarter worth $43,000. Finally, Rothschild Investment LLC raised its stake in DexCom by 59.9% during the 3rd quarter. Rothschild Investment LLC now owns 654 shares of the medical device company's stock valued at $44,000 after purchasing an additional 245 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Trading Up 3.0%

Shares of DXCM stock opened at $72.34 on Friday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The stock has a market cap of $27.91 billion, a price-to-earnings ratio of 30.91, a P/E/G ratio of 1.16 and a beta of 1.40. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The firm has a fifty day moving average of $64.05 and a 200-day moving average of $66.39.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.17 billion. During the same quarter in the prior year, the company posted $0.32 EPS. The business's revenue was up 15.0% on a year-over-year basis. On average, equities research analysts forecast that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Michael Jon Brown sold 1,700 shares of the company's stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the sale, the executive vice president owned 111,204 shares of the company's stock, valued at approximately $7,010,300.16. This represents a 1.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the company's stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the sale, the insider directly owned 382,482 shares in the company, valued at approximately $27,538,704. The trade was a 6.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 32,871 shares of company stock worth $2,306,638. 0.28% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Evercore upgraded shares of DexCom from an "in-line" rating to an "outperform" rating and set a $90.00 target price for the company in a research note on Tuesday, March 24th. Weiss Ratings upgraded shares of DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, March 4th. Wells Fargo & Company cut their target price on shares of DexCom from $93.00 to $85.00 and set an "overweight" rating for the company in a research note on Friday, February 13th. Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a research note on Friday, May 1st. Finally, William Blair upgraded shares of DexCom to a "strong-buy" rating in a research note on Friday, May 15th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $82.42.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.